Avidity biosciences announces upcoming presentations at 27th international hybrid annual congress of world muscle society

San diego , oct. 6, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the company will be presenting five poster presentations including the marina™ study design for myotonic dystrophy type 1 and preclinical and real-world data from the facioscapulohumeral muscular dystrophy (fshd) and duchenne muscular dystrophy (dmd) programs. the posters will be presented at the 27th international hybrid annual congress of the world muscle society (wms), taking place october 11-15, 2022 in halifax, nova scotia, canada.
RNA Ratings Summary
RNA Quant Ranking